(NASDAQ: SPTX) Seaport Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.35%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.91%.
Seaport Therapeutics's earnings in 2026 is N/A.On average, 8 Wall Street analysts forecast SPTX's earnings for 2026 to be -$259,082,509, with the lowest SPTX earnings forecast at -$621,650,277, and the highest SPTX earnings forecast at -$157,379,817. On average, 8 Wall Street analysts forecast SPTX's earnings for 2027 to be -$140,506,988, with the lowest SPTX earnings forecast at -$157,904,416, and the highest SPTX earnings forecast at -$101,172,740.
In 2028, SPTX is forecast to generate -$144,147,065 in earnings, with the lowest earnings forecast at -$185,708,184 and the highest earnings forecast at -$95,552,032.